Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: A pharmacologically based regimen

Cancer

Volumn 88, Issue 9, 2000, Pages 2037-2041

  Sternberg, David W ^a   Aird, William ^a,c   Neuberg, Donna ^c   Thompson, Lynn ^a,c   MacNeill, Kimberly ^a,c   Amrein, Philip ^b   Shulman, Lawrence N ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Acute myelogenous leukemia; Ara C; Disease remission; Mitoxantrone

Indexed keywords

CYTARABINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALKYLATION; ARTICLE; BASE PAIRING; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETIC RISK; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; REMISSION; TUMOR RECURRENCE;

ADULT; AGE FACTORS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CEREBELLAR DISEASES; CYTARABINE; DEATH, SUDDEN, CARDIAC; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; REMISSION INDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034194443     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2037::AID-CNCR8>3.0.CO;2-K     Document Type: Article

References (17)

1. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995;13:560-9.
2. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
3. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968;32:507-23.
4. Plunkett W, Gandhi V. Cellular pharmacodynamics of anti-cancer drugs. Semin Oncol 1993;20:5063.
5. Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma 1993;10 (Suppl):115-21.
6. Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 1988;22:205-10.
7. Brito-Babapulle F, Catovsky D, Newland AC, Goldman JM, Galton DAG. Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Semin Oncol 1987;14(Suppl 1):51-2.
8. Amadori S, Meloni G, Petti MC, Papa G, Miniero R, Mandelli F. Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. Leukemia 1989;3:112-4.
9. Davis CL, Rohatiner AZ, Lim J, Whelan JS, Oza AM, Amess J, et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 1993;83:404-11.
10. de la Serna J, Francisco Tomas J, Solano C, Garcia de Paredes ML, Campbell J, Grande C, et al. Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 1997; 25:365-72.
11. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani H, Testoni N, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemias. Leukemia 1994;8: 1842-6.
12. Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jager U, Knobl P, et al. FIAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 1996;73:265-71.
13. Vignetti M, Orsini E, Petti MC, Moleti ML, Andrizzi C, Pinto RM, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol 1996;7:933-8.
14. Auerbach M. Acute myeloid leukemia in patients more than 50 years of age: special considerations in diagnosis, treatment, and prognosis. Am J Med 1994;96:180-5.
15. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995;332:1671-7.
16. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995;332:1678-83.
17. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AMI. 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92: 2322-33.